Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004211 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer
A Phase 1 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT00004211 is a Phase 1 study that has completed, run by Duke University. The registered enrollment target is 17 participants.
The verdict
NCT00004211, a Phase 1 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy in treating patients who have metastatic prostate cancer.
Interventions
- BIOLOGICAL PSA RNA-pulsed dendritic cell vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 1999-07 |
| Est. Completion | 2002-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004211
The ClinicalTrials.gov registry entry for NCT00004211 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PSA RNA-pulsed dendritic cell vaccine is the first listed.
NCT00004211 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004211 about?
NCT00004211 is a clinical study titled "Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer". RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy in treating patients who have metastatic prostate cancer.
What is the current status of trial NCT00004211?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 1999-07. Estimated completion is 2002-01.
What interventions are being tested in trial NCT00004211?
The interventions under investigation include: PSA RNA-pulsed dendritic cell vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00004211?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.